Quick Answer
SUTRO BIOPHARMA, INC. reported Operating Income Loss of -$158.37 million for the year ending 2025.
- SUTRO BIOPHARMA, INC. showed an increase of +33.6% in Operating Income Loss from 2024 to 2025.
- This data is from SUTRO BIOPHARMA, INC.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2017: -$1.07 million | Q1 2018: -$11.70 million | Q2 2018: -$12.09 million | Q3 2018: -$10.16 million | Q1 2019: -$14.27 million | Q2 2019: -$13.69 million | Q3 2019: -$12.74 million | Q1 2020: -$19.18 million | Q2 2020: -$16.42 million | Q3 2020: -$10.62 million | Q1 2021: -$19.01 million | Q2 2021: -$9.81 million | Q3 2021: -$34.67 million | Q1 2022: -$39.13 million | Q2 2022: -$19.38 million | Q3 2022: -$21.21 million | Q1 2023: -$42.24 million | Q2 2023: -$46.18 million | Q3 2023: -$44.01 million | Q1 2024: -$56.59 million | Q2 2024: -$48.69 million | Q3 2024: -$67.92 million | Q1 2025: -$68.51 million | Q2 2025: -$3.35 million | Q3 2025: -$48.46 million.
- Over the full 10 years of available data (2016 to 2025), SUTRO BIOPHARMA, INC.'s Operating Income Loss has declined by 11,710.5%.
- Historical annual values: Fiscal year 2025: -$158.37 million | Fiscal year 2024: -$238.45 million | Fiscal year 2023: -$89.28 million | Fiscal year 2022: -$128.94 million | Fiscal year 2021: -$98.52 million | Fiscal year 2020: -$71.06 million | Fiscal year 2019: -$55.47 million | Fiscal year 2018: -$37.22 million | Fiscal year 2017: -$19.27 million | Fiscal year 2016: $1.36 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: